ArrowMark Colorado Holdings’s Dianthus Therapeutics DNTH Stock Holding History

ArrowMark Colorado Holdings’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.74M	Hold	20,788	–	–	0.05%	226
2025 Q4	$857K	Hold	20,788	–	–	0.02%	267
2025 Q3	$818K	Hold	20,788	–	–	0.02%	257
2025 Q2	$387K	Hold	20,788	–	–	0.01%	282
2025 Q1	$377K	Hold	20,788	–	–	0.01%	278
2024 Q4	$453K	Hold	20,788	–	–	0.01%	284
2024 Q3	$569K	Hold	20,788	–	–	0.01%	271
2024 Q2	$538K	Hold	20,788	–	–	0.01%	285
2024 Q1	$624K	Hold	20,788	–	–	0.01%	283
2023 Q4	$216K	Hold	20,788	–	–	﹤0.01%	294
2023 Q3	$284K	Buy	+20,788	New	+$262K	﹤0.01%	288

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ArrowMark Colorado Holdings's DNTH Position: Q1 2026 in Review

ArrowMark Colorado Holdings held its Dianthus Therapeutics (DNTH) position steady in Q1 2026 at 20,788 shares worth $1.74M. The position accounts for 0.05% of the portfolio, ranked #226.

ArrowMark Colorado Holdings first reported a position in DNTH in Q3 2023 and has held it in 11 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

ArrowMark Colorado Holdings held 20,788 shares of Dianthus Therapeutics worth $1.74M as of Q1 2026.
ArrowMark Colorado Holdings left its Dianthus Therapeutics share count unchanged in Q1 2026.
Dianthus Therapeutics made up 0.05% of ArrowMark Colorado Holdings's portfolio in Q1 2026, its #226 holding.
ArrowMark Colorado Holdings first reported a position in Dianthus Therapeutics in Q3 2023 and has held it in 11 quarters since.
241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q1 2026, filed 15 May 2026.